Additional TZD members, such as Troglidazone, Pioglitazone, Rivoglitazone, and variants of the same pharmacocore were used in the treatment of T2DM patients, and all behave as PPARγ full agonists. This evidence concerns the gene PPARG and type 2 diabetes mellitus.